NSE filing, NSE: ALKEM. Summary written from the filing by ALFA Finder's alert engine.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,049.00
- Market cap
- ₹60,368 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 28.0×Sector 46.1×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Legal & Regulatory
Alkem Laboratories has initiated a forensic audit by Grant Thornton Bharat LLP following alleged misappropriation of funds by a former employee.
Alkem Laboratories Other Announcement
Alkem Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements. This document details the company's equity structure.
Alkem Laboratories Management Change
Alkem Laboratories appointed Laxmikant Tiwari and Nilesh Vartak as Senior Management Personnel effective 12 October 2026. The appointments strengthen pharmaceutical operations and supply chain leadership.
Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Other management change announcements
All →Equitas Small Finance Bank Management Change
Equitas Small Finance Bank's MD & CEO P. N. Vasudevan resigned effective upon successor appointment. The Board will recommend suitable candidates subject to RBI approval.
Integrated Proteins Management Change
Integrated Proteins appointed Ms. Arushi Aggarwal as Company Secretary and Compliance Officer, effective 29 October 2026. The appointment was approved at a board meeting as a Key Managerial Personnel change.
Suraj Management Change
Suraj Limited appointed Mr. Mayank Balvantbhai Rami as Company Secretary and Compliance Officer effective November 1, 2026. The board approved this KMP appointment on October 29, 2026.
Superior Finlease Management Change
Superior Finlease disclosed that Mr. Krishan Gopal Sharma resigned as CFO and KMP effective 28 Oct 2026 due to personal commitments. No successor is named yet.
Vertex Securities Management Change
Vertex Securities appointed Ms. Unni as Independent Director and Mr. Iyer as CFO, effective October 2026. Both roles were approved at the 28 October board meeting.
Kirloskar Brothers Management Change
Kirloskar Brothers' Independent Directors Vivek Pendharkar and Rekha Sethi completed their 5-year terms on 28 Oct 2026. They ceased from the Board and all committees.